“though I agree with Geoff that eventually AI will have a big impact on drug design. Perhaps with current techniques, perhaps not; we will have to see.”
Our reading, the sentence that was checked:
AI will eventually have a big impact on drug design, possibly but not necessarily with current techniques.
Assessment: Unresolved No deadline stated on 2026-10-29 Evidence as of
Where and when Gary Marcus wrote it
Marcus on AI, What was 60 Minutes thinking, in that interview with Geoff Hinton?, paragraph 109.
- Said
- Source observed
- live page, full text, public
- Evidence as of
- the cutoff for this assessment
- Assessment recorded
- assessment marcus-what-was-60-minutes-thinking-in-that-06078f-a1
We recorded 20 claims from this post. See every claim from this post.
The wording above is the version this site observed on 2026-10-29. The source may have been edited after 2023-10-10. This page does not claim the wording was captured then.
What the claim commits to
- Kind
- Forecast
- Deadline, as the speaker wrote it
- “eventually”
- Deadline state when assessed
- No deadline stated
- Deadline state on 2026-10-29
- No deadline stated (the release’s reference date)
Conditions
- not necessarily with current techniques (qualifier, stated by the speaker)
From the speaker
- eventually
- AI will have a big impact on drug design
- Perhaps with current techniques, perhaps not
Our interpretation
- Eventually supplies no deadline.
- The allowance for future techniques broadens the forecast; it is not an antecedent that must occur before scoring.
- Big impact means a substantial demonstrated change in drug-design practice, productivity or successful therapeutic output.
- One promising candidate is evidence of progress, but does not by itself establish a substantial impact across drug design.
Counts as supported if: Public evidence establishes substantial, sustained changes in drug-design productivity or practice attributable to AI, or substantial therapeutic output from AI-designed drugs.
Counts as contradicted if: No finite period without success contradicts this unrestricted eventual forecast. An adverse trial result or failure of current techniques is insufficient.
Retrospective: these criteria were written after the outcome was public.
Current assessment
Did the forecast come true?
Outcome: Unresolved
The record was checked, and the evidence available by the cutoff does not settle it.
Scored on a plain reading. The speaker named no measure for this claim, so it was judged on the reading an informed reader would take, stated below under our interpretation. Both reviews had to find that reading fair.
- Evidence as of
- Deadline state when assessed
- No deadline stated
- Assessment recorded
- Policy version
- 2026-10-28.7
Rationale
Rentosertib's published trial results and subsequent Phase III start are meaningful progress. They do not meet the stated early-resolution rule for substantial realized impact on drug design. Marcus gave no deadline and explicitly allowed future techniques, so the absence of a decisive event by 2026-10-28 cannot count as failure.
Limitations
- The threshold for substantial impact is an evaluator interpretation.
- The evidence search is not an exhaustive census of every AI-assisted drug-design program.
- A company milestone announcement cannot by itself establish industry-wide productivity gains.
Evidence (2 items)
Context only: Nature Medicine,
warrants further investigation
Why it matters here: The reported Phase IIa results include an encouraging lung-function signal for an AI-designed molecule. The authors call for larger, longer trials; this establishes progress rather than the forecast's broad impact.
- Publisher
- Nature Medicine
- Kind of source
- Peer-reviewed paper
- Describes events of
- Public from
Context only: Insilico Medicine,
developed utilizing generative AI.
Why it matters here: The announcement reports first dosing in Phase III and states that rentosertib remains investigational without regulatory approval. This is a dated development milestone, but it does not establish the substantial realized impact required for early resolution.
- Publisher
- Insilico Medicine
- Kind of source
- Company disclosure: the company describing itself, not an independent finding
- Describes events of
- Public from
What would settle it
Dated primary evidence of substantial therapeutic output or independently substantiated, sustained adoption or productivity gains attributable to AI in drug design.
Where it was said (1)
Said once in the sources this register covers.
: Marcus on AI, What was 60 Minutes thinking, in that interview with Geoff Hinton?
though I agree with Geoff that eventually AI will have a big impact on drug design. Perhaps with current techniques, perhaps not; we will have to see.
- Where
- paragraph 109
- Published
- 2023-10-10
- Source observed
- , live page
- Access
- full text, public
History
Assessment versions
- Assessment marcus-what-was-60-minutes-thinking-in-that-06078f-a1: Current. Outcome: Unresolved. Evidence as of 2026-10-28. Public date not recorded.
Recorded events
Assessment publishedBy this site
First assessment published after both reviews and the final-text check passed.
About assessment marcus-what-was-60-minutes-thinking-in-that-06078f-a1.